BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2023 6:01:48 AM | Browse: 569 | Download: 1566
Publication Name World Journal of Clinical Cases
Manuscript ID 87953
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report
Manuscript Source Unsolicited Manuscript
All Author List Rong-Ting Wu, Ji-Cheng Zhang, Cheng-Nan Fang, Xiao-Yu Qi, Jin-Fei Qiao, Ping Li and Li Su
ORCID
Author(s) ORCID Number
Rong-Ting Wu http://orcid.org/0009-0002-2662-2054
Ji-Cheng Zhang http://orcid.org/0009-0009-3755-4502
Cheng-Nan Fang http://orcid.org/0009-0003-3343-5940
Xiao-Yu Qi http://orcid.org/0009-0002-6345-8855
Jin-Fei Qiao http://orcid.org/0009-0002-4304-1606
Ping Li http://orcid.org/0000-0002-8900-3595
Li Su http://orcid.org/0000-0002-1136-8826
Funding Agency and Grant Number
Corresponding Author Li Su, Doctor, Deputy Director, Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, No. 120, Wanshui Road, Shushan District, Hefei 230022, Anhui Province, China. 13615606829@163.com
Key Words Low-grade myofibroblastic sarcoma; Pancreas; Pembrolizumab; Anlotinib; Immunohistochemistry; Pathology; Case report
Core Tip Low-grade myofibroblastic sarcoma (LGMS) is a rare spindle cell sarcoma with myofibroblastic differentiation. It is predominantly located in the head, neck, and extremities, whereas less frequently in the abdominal cavity, especially the pancreatic region. LGMS is characterized by a low-grade malignancy and low risk of recurrence and metastases. To date, complete surgical resection remains the primary treatment modality. Despite chemoradiotherapy showing anti-tumor activity for the treatment of postoperative recurrence and metastasis, it remains controversial. Until recently, no effective treatment for LGMS patients intolerant to chemoradiotherapy has been well established. This article aims to explore the new idea of LGMS based on literature obtained from PubMed and a clinical case.
Publish Date 2023-12-14 06:01
Citation Wu RT, Zhang JC, Fang CN, Qi XY, Qiao JF, Li P, Su L. Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report. World J Clin Cases 2023; 11(35): 8385-8391
URL https://www.wjgnet.com/2307-8960/full/v11/i35/8385.htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i35.8385
Full Article (PDF) WJCC-11-8385-with-cover.pdf
Full Article (Word) WJCC-11-8385.docx